168 related articles for article (PubMed ID: 10854579)
1. Opposite effects of glutamate antagonists and antiparkinsonian drugs on the activities of DOPA decarboxylase and 5-HTP decarboxylase in the rat brain.
Fisher A; Starr MS
Brain Res; 2000 Jun; 868(2):268-74. PubMed ID: 10854579
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of NMDA and non-NMDA antagonists on the activity of aromatic L-amino acid decarboxylase activity in the nigrostriatal dopamine pathway of the rat.
Fisher A; Biggs CS; Starr MS
Brain Res; 1998 May; 792(1):126-32. PubMed ID: 9593857
[TBL] [Abstract][Full Text] [Related]
3. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra.
Biggs CS; Fisher A; Starr MS
Synapse; 1998 Nov; 30(3):309-17. PubMed ID: 9776134
[TBL] [Abstract][Full Text] [Related]
4. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
5. Effects of glutamate antagonists on the activity of aromatic L-amino acid decarboxylase.
Fisher A; Biggs CS; Starr MS
Amino Acids; 1998; 14(1-3):43-9. PubMed ID: 9871440
[TBL] [Abstract][Full Text] [Related]
6. Dual effects of L-3,4-dihydroxyphenylalanine on aromatic L-amino acid decarboxylase, dopamine release and motor stimulation in the reserpine-treated rat: evidence that behaviour is dopamine independent.
Fisher A; Biggs CS; Eradiri O; Starr MS
Neuroscience; 2000; 95(1):97-111. PubMed ID: 10619466
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine.
Deep P; Dagher A; Sadikot A; Gjedde A; Cumming P
Synapse; 1999 Dec; 34(4):313-8. PubMed ID: 10529725
[TBL] [Abstract][Full Text] [Related]
8. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
[TBL] [Abstract][Full Text] [Related]
9. NMDA receptor antagonists increase the release of dopamine in the substantia nigra of reserpine-treated rats.
Biggs CS; Fowler LJ; Whitton PS; Starr MS
Eur J Pharmacol; 1996 Mar; 299(1-3):83-91. PubMed ID: 8901010
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of intrastriatal and intranigral injections of glutamate antagonists on motor behaviour in the reserpine-treated rat.
Kaur S; Starr MS
Neuroscience; 1997 Jan; 76(2):345-54. PubMed ID: 9015320
[TBL] [Abstract][Full Text] [Related]
11. Stress-induced increase in extracellular dopamine in striatum: role of glutamatergic action via N-methyl-D-aspartate receptors in substantia nigra.
Castro SL; Zigmond MJ
Brain Res; 2001 May; 901(1-2):47-54. PubMed ID: 11368949
[TBL] [Abstract][Full Text] [Related]
12. Restorative effects of glutamate antagonists in experimental parkinsonism.
Archer T; Palomo T; Fredriksson A
Amino Acids; 2002; 23(1-3):71-85. PubMed ID: 12373521
[TBL] [Abstract][Full Text] [Related]
13. MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats.
Jonkers N; Sarre S; Ebinger G; Michotte Y
Brain Res; 2002 Feb; 926(1-2):149-55. PubMed ID: 11814417
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
Nash JE; Brotchie JM
Mov Disord; 2002 May; 17(3):455-66. PubMed ID: 12112191
[TBL] [Abstract][Full Text] [Related]
15. Effects of the antiparkinsonian drug budipine on central neurotransmitter systems.
Klockgether T; Wüllner U; Steinbach JP; Petersen V; Turski L; Löschmann PA
Eur J Pharmacol; 1996 Apr; 301(1-3):67-73. PubMed ID: 8773448
[TBL] [Abstract][Full Text] [Related]
16. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
Sarre S; Lanza M; Makovec F; Artusi R; Caselli G; Michotte Y
Eur J Pharmacol; 2008 Apr; 584(2-3):297-305. PubMed ID: 18342306
[TBL] [Abstract][Full Text] [Related]
17. Demonstration of immunohistochemical and immunochemical cross-reactivity of L-histidine and L-dopa decarboxylases using antibodies against the two enzymes.
Ando-Yamamoto M; Hayashi H; Taguchi Y; Fukui H; Watanabe T; Wada H
Biochem Biophys Res Commun; 1986 Nov; 141(1):306-12. PubMed ID: 3541929
[TBL] [Abstract][Full Text] [Related]
18. The parkinsonian neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) mediates release of l-3,4-dihydroxyphenylalanine (l-DOPA) and inhibition of l-DOPA decarboxylase in the rat striatum: a microdialysis study.
Foster SB; Wrona MZ; Han J; Dryhurst G
Chem Res Toxicol; 2003 Oct; 16(10):1372-84. PubMed ID: 14565778
[TBL] [Abstract][Full Text] [Related]
19. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies.
Danysz W; Parsons CG; Kornhuber J; Schmidt WJ; Quack G
Neurosci Biobehav Rev; 1997 Jul; 21(4):455-68. PubMed ID: 9195603
[TBL] [Abstract][Full Text] [Related]
20. N-methyl-D-aspartate receptor blockade attenuates D1 dopamine receptor modulation of neuronal activity in rat substantia nigra.
Huang KX; Bergstrom DA; Ruskin DN; Walters JR
Synapse; 1998 Sep; 30(1):18-29. PubMed ID: 9704877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
